ArticleWorld journal of microbiology & biotechnology2026
Genomic comparison of Staphylococcus aureus isolates from patients with bacteraemia and infective endocarditis at public hospitals in Gauteng, South Africa.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus (S. aureus) is a leading cause of bacteraemia and infective endocarditis worldwide, posing significant public health challenges in resource-limited low- and middle-income countries (LMICs). However, whether specific genomic factors influence the development of S. aureus infective endocarditis (SAIE) during S. aureus bacteraemia (SAB) remains unclear. Thus, the study aimed to determine whether clinical SAIE isolates were genomically distinguishable from SAB isolates originating from public hospitals in Gauteng, South Africa. Seventy-seven (54 SAB, 23 SAIE) bloodstream isolates were characterised to assess antimicrobial susceptibility (VITEK®2 system), biofilm formation (crystal violet assay), virulence genes (multiplex-polymerase chain reactions) and genetic relatedness (pulsed-field gel electrophoresis), while 12 representative isolates underwent whole-genome sequencing. A higher SAIE (29.9%) prevalence than previously reported in South Africa was observed, with cases linked to young male persons who inject drugs (P < 0.01). While the SAB and SAIE groups did not differ in virulence profiles, SAB isolates demonstrated higher resistance rates to gentamicin and clindamycin than SAIE isolates (P < 0.05). The endemic Panton-Valentine leukocidin-positive sequence type (ST) 152, clonal complex (CC) 152 lineage predominated in SAIE isolates, while the pandemic CC8, encompassing ST239 and ST612, was exclusive to SAB isolates. Overall, SAB and SAIE isolates were not clearly distinguished by the markers assessed, suggesting that SAIE development may reflect the combined effects of bacterial traits, host susceptibility and exposure-related risk factors, rather than a distinct SAIE-specific genomic profile. These findings highlight the need for continued genomic surveillance of circulating S. aureus lineages to inform targeted infection-control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.